Evidence map›Paper›PMID 42572748›Full record

ReviewClinical, cosmetic and investigational dermatology2026

Acral Vitiligo: A Comprehensive Review of Clinical Features, Pathogenesis, and Novel Therapeutic Advances.

Ting Song, Shun Guo, Jia Liu, Cheng Tan, Yue Shi

Abstract readReview
In one paragraph

Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ting SongDepartment of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Shun GuoDepartment of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Jia LiuDepartment of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Cheng TanDepartment of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Yue ShiDepartment of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acral vitiligo, a distinct subtype predominantly affecting the distal extremities (hands and feet), presents significant clinical challenges due to its treatment resistance and profound psychosocial impact. This narrative review systematically synthesizes current knowledge on the epidemiology, unique clinical presentations, and the specific pathophysiological mechanisms underlying this recalcitrant variant. We critically appraise recent advances in diagnosis and treatment, integrating findings from clinical studies, experimental researches, and case reports. The central aim is to provide a nuanced, evidence-based understanding of acral vitiligo to guide clinical management. We critically evaluate contemporary treatment modalities, including the emerging roles of Janus kinase (JAK) inhibitors and biologic agents, while also addressing the crucial dimension of psychosocial burden. Finally, we delineate key knowledge gaps-particularly the lack of acral‑specific outcome measures and head‑to‑head comparative trials-and propose future research directions to improve outcomes for patients with this therapeutically orphaned subtype.

Indexed as

acral vitiligobiologicsJanus kinase inhibitorspathogenesistreatment resistance

Identifiers

PMID42572748
PMCPMC13453360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.